Ranked #1 in 8 out of the 10 evaluated specialties by U.S. News
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Severe Combined Immunodeficiency (SCID)
The rare genetic disorder severe combined immunodeficiency (SCID)—popularized in the 1976 movie “The Boy in the Plastic Bubble”—is actually a group of several different diseases. There are more than 10 documented types of SCID, all of which:
Because SCID all but eliminates a child’s immune system—the body’s built-in defense against infection—children with SCID are at high risk of developing severe infections.
Although SCID remains a very serious illness, treatment options have come a long way since the debut of “The Boy in the Plastic Bubble.” New approaches in diagnosing and managing the disorder are providing new hope for children and families.
How Boston Children's Hospital approaches SCID
Boston Children’s has a long history of caring for children with complex disorders of the immune system. Clinicians in our Division of Allergy and Immunology are international leaders in understanding and treating rare conditions like SCID.
Most children with SCID receive a stem cell transplant (also known as a bone marrow transplant), so that they can develop new white blood cells, replenishing their immune systems. The Dana-Farber/Boston Children's Cancer and Blood Disorders Center's Stem Cell Transplant Center—one of the first pediatric transplant centers in the nation—performs more than 90 stem cell transplants each year.
In addition, Boston Children’s is helping to lead an international gene therapy trial for SCID. The trial—which transplants genetically modified stem cells from a child’s own bone marrow—may signify a promising new approach to fighting and defeating the disease.
SCID: Reviewed by Francisco Bonilla, MD, and Luigi Notarangelo, MD.
© Boston Children's Hospital; posted in 2014
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”